Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

Inclusion Criteria: 1. In a pulmonary function test of Screening Test II, FEV1.0 was less than 70% of predict normal and FEV1.0 was less than 70% of FVC. 2. In the reversibility test of Screening Test II, FEV1.0 was improved by 10% or more at 1 hour after inhalation of 2 puffs of an anticholinergic agent (Tersigan ® Aerozol) 3. History of smoking (\< no. of cigarettes a day x no. of years of smoking \> = 200 or more) 4. 40 years of age or older 5. Regardless of sex and the length of disease period Exclusion Criteria: 1. A history of bronchial asthma 2. A history of atopic disease, such as allergic rhinitis 3. Blood eosinophil of 440/µl or more 4. Continuous use of steroid drugs (oral administration, inhalation or injection) at a dose equivalent to over 5 mg daily of prednisolone 5. A history of respiratory infection, including virus infection within 1 month before study initiation 6. Tuberculosis, lung cancer or a history of pneumonectomy 7. Glaucoma 8. Under treatment of benign prostatic hypertrophy 9. Hypersensitivity to anticholinergic agents or sympathomimetics 10. Difficulty in expectoration of sputum 11. Serious heart disease, renal disease, hepatic disease, endocrine disease or metabolic disease 12. Use of any β blockers 13. A history of myocardial infarction within the past 1 year 14. A history of heart failure, cor pulmonale or arrhythmia requiring medication within the past 3 years 15. A history of drug abuse or alcoholism 16. Treatment of psychotic disease 17. Pregnancy, possible pregnancy or lactation 18. A history of participation in any other clinical studies within the past 6 months 19. Judgment by the investigator that the patient is ineligible for inclusion in the present study